Antipsychotics of interest to the National Pregnancy Registry include:
- Abilify (aripiprazole)
- Aristada (aripiprazole lauroxil)
- Aristada Initio (aripiprazole lauroxil)
- Geodon (ziprasidone)
- Invega (paliperidone)
- Latuda (lurasidone)
- Lybalvi (olanzapine & samidorphan)
- Rexulti (brexpiprazole)
- Risperdal (risperidone)
- Seroquel (quetiapine)
- Symbyax (olanzapine & fluoxetine)
- Zyprexa (olanzapine)
Required Sponsorship Disclosures:
Current Sponsors: Alkermes, Inc. (2016-Present); Johnson & Johnson/Janssen Pharmaceuticals, Inc (2019-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Supernus Pharmaceuticals (2021-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).
Past Sponsors: Forest/Actavis/Allergan (2016-2018, declined to sponsor: 2018-Present); Aurobindo Pharma (2020-2022, declined to sponsor: 2022-Present); AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); AuroMedics Pharma LLC (2021-2022, declined to sponsor: 2022-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present)
Declined to sponsor: Apotex, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals; Vanda Pharmaceuticals Inc.
Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.